TY - JOUR
T1 - Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer
AU - Schwartz, Marc D.
AU - Valdimarsdottir, Heiddis B.
AU - Peshkin, Beth N.
AU - Mandelblatt, Jeanne
AU - Nusbaum, Rachel
AU - Huang, An Tsun
AU - Chang, Yaojen
AU - Graves, Kristi
AU - Isaacs, Claudine
AU - Wood, Marie
AU - McKinnon, Wendy
AU - Garber, Judy
AU - McCormick, Shelley
AU - Kinney, Anita Y.
AU - Luta, George
AU - Kelleher, Sarah
AU - Leventhal, Kara Grace
AU - Vegella, Patti
AU - Tong, Angie
AU - King, Lesley
PY - 2014/3/1
Y1 - 2014/3/1
N2 - Purpose: Although guidelines recommend in-person counseling before BRCA1/BRCA2 gene testing, genetic counseling is increasingly offered by telephone. As genomic testing becomes more common, evaluating alternative delivery approaches becomes increasingly salient. We tested whether telephone delivery of BRCA1/2 genetic counseling was noninferior to in-person delivery. Patients and Methods: Participants (women age 21 to 85 years who did not have newly diagnosed or metastatic cancer and lived within a study site catchment area) were randomly assigned to usual care (UC; n = 334) or telephone counseling (TC; n = 335). UC participants received in-person pre- and post-test counseling; TC participants completed all counseling by telephone. Primary outcomes were knowledge, satisfaction, decision conflict, distress, and quality of life; secondary outcomes were equivalence of BRCA1/2 test uptake and costs of delivering TC versus UC. Results: TC was noninferior to UC on all primary outcomes. At 2 weeks after pretest counseling, knowledge (d = 0.03; lower bound of 97.5% CI, -0.61), perceived stress (d = -0.12; upper bound of 97.5% CI, 0.21), and satisfaction (d = -0.16; lower bound of 97.5% CI, -0.70) had group differences and confidence intervals that did not cross their 1-point noninferiority limits. Decision conflict (d = 1.1; upper bound of 97.5% CI, 3.3) and cancer distress (d = -1.6; upper bound of 97.5% CI, 0.27) did not cross their 4-point noninferiority limit. Results were comparable at 3 months. TC was not equivalent to UC on BRCA1/2 test uptake (UC, 90.1%; TC, 84.2%). TC yielded cost savings of $114 per patient. Conclusion: Genetic counseling can be effectively and efficiently delivered via telephone to increase access and decrease costs.
AB - Purpose: Although guidelines recommend in-person counseling before BRCA1/BRCA2 gene testing, genetic counseling is increasingly offered by telephone. As genomic testing becomes more common, evaluating alternative delivery approaches becomes increasingly salient. We tested whether telephone delivery of BRCA1/2 genetic counseling was noninferior to in-person delivery. Patients and Methods: Participants (women age 21 to 85 years who did not have newly diagnosed or metastatic cancer and lived within a study site catchment area) were randomly assigned to usual care (UC; n = 334) or telephone counseling (TC; n = 335). UC participants received in-person pre- and post-test counseling; TC participants completed all counseling by telephone. Primary outcomes were knowledge, satisfaction, decision conflict, distress, and quality of life; secondary outcomes were equivalence of BRCA1/2 test uptake and costs of delivering TC versus UC. Results: TC was noninferior to UC on all primary outcomes. At 2 weeks after pretest counseling, knowledge (d = 0.03; lower bound of 97.5% CI, -0.61), perceived stress (d = -0.12; upper bound of 97.5% CI, 0.21), and satisfaction (d = -0.16; lower bound of 97.5% CI, -0.70) had group differences and confidence intervals that did not cross their 1-point noninferiority limits. Decision conflict (d = 1.1; upper bound of 97.5% CI, 3.3) and cancer distress (d = -1.6; upper bound of 97.5% CI, 0.27) did not cross their 4-point noninferiority limit. Results were comparable at 3 months. TC was not equivalent to UC on BRCA1/2 test uptake (UC, 90.1%; TC, 84.2%). TC yielded cost savings of $114 per patient. Conclusion: Genetic counseling can be effectively and efficiently delivered via telephone to increase access and decrease costs.
UR - http://www.scopus.com/inward/record.url?scp=84899149442&partnerID=8YFLogxK
U2 - 10.1200/JCO.2013.51.3226
DO - 10.1200/JCO.2013.51.3226
M3 - Article
C2 - 24449235
AN - SCOPUS:84899149442
SN - 0732-183X
VL - 32
SP - 618
EP - 626
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 7
ER -